DGAP-News: STADA Arzneimittel AG / Key word(s): Bond/Miscellaneous STADA Arzneimittel AG: Voting results of the bondholders' meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items 17.07.2018 / 12:05 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Bad Vilbel, July 17, 2018 - STADA Arzneimittel Aktiengesellschaft ("STADA" or the "Issuer") hereby announces the voting results of the meeting on July 17, 2018 (the "Bondholders' Meeting") of the bondholders (the "Bondholders ") of the EUR 300,000,000 1.750% Bonds, due 2022, ISIN XS1213831362, Common Code 121383136, WKN A14KJP (the "Bonds"). The Bondholders decided to appoint One Square Advisory Services GmbH as joint representative according to the resolution proposal of the chairman of the meeting and the Issuer under agenda item III as amended at the Bondholders' Meeting. Since the Bondholders' Meeting did not reach the quorum required for the resolutions on the authorization of the joint representative to accede to the Intercreditor Agreement and on certain technical changes to the bond terms and conditions, the agenda items IV and V have been adjourned to September 18, 2018 as proposed by the chairman of the meeting and the Issuer. The time until then is supposed to be used to mobilize a sufficient number of Bondholders to participate. No further resolutions were passed. Further details of the Bondholders' Meeting, including the voting results for each agenda item, are available on the STADA website at www.stada.com/investor-relations/bonds.html. About STADA Arzneimittel AG STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide. Additional information for journalists: STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-165 [IMAGE] / Fax: +49 (0) 6101 603-215 [IMAGE] / E-Mail: [email protected] Or visit us on the Internet at www.stada.com Additional information for capital market participants: STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 [IMAGE] / Fax: +49 (0) 6101 603-215 [IMAGE] / E-mail: [email protected] Or visit us on the Internet at www.stada.com --------------------------------------------------------------------------- 17.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: [email protected] Internet: www.stada.de ISIN: DE0007251803 WKN: 725180 Listed: Regulated Market in Dusseldorf, Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 705249 17.07.2018